Acute arterial thrombosis after escalated‐dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony‐stimulating factor: A possible new recombinant granulocyte colony‐stimulating factor toxicity

Cancer

Volumn 70, Issue 11, 1992, Pages 2699-2702

  Conti, John A ^a,b   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

arterial thrombosis; chemotherapy; colony stimulating factors; hypercoagulable state; leukocytosis; malignant bladder neoplasms

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

AGED; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLADDER TUMOR; CANCER SURVIVAL; CASE REPORT; COMBINATION CHEMOTHERAPY; HUMAN; HYPERCOAGULABILITY; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CASE REPORT; CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMAN; MALE; METHOTREXATE; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOSIS; VINBLASTINE;

EID: 0026485559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19921201)70:11<2699::AID-CNCR2820701122>3.0.CO;2-C     Document Type: Article

References (35)

1. Current status of chemotherapy of urothelial tract tumors
2. M‐VAC (methotrexate, vinblastine, Adriamycin and cisplatin) for advanced transitional cell carcinoma of the urothelium
3. M‐VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response
4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
5. A prospective randomized trial comparing MVAC and CI‐SCA chemotherapy for patients with metastatic urothelial tumors
6. Hematopoietic growth factors in cancer treatment
7. Phase I study of granulocyte colony‐stimulating factor in patients with transitional cell carcinoma of the urothelium
8. Effect of granulocyte colony‐stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional‐cell carcinoma of the urothelium
9. Hematopoietic growth factors: biology and clinical applications
10. Average relative dose intensity and the impact on design of clinical trials
11. High dose methotrexate, vinblastine, Adriamycin and cisplatin for urothelial tract tumors [abstract]
12. Escalated therapy for refractory urothelial tumors: methotrexate‐vinblastine‐doxorubicin‐cisplatin plus unglycosylated recombinant human granulocyte‐macrophage colony‐stimulating factor
13. Vascular toxicity associated with antineoplastic agents
14. Hematologic problems in patients with cancer and chronic inflammatory disorders
15. Disorders of hemostasis and thrombosis: pathogenesis of thrombosis
16. Peripheral arterial occlusive disease
17. The hypercoagulable states
18. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism
19. Role of leukocytes in thrombosis
20. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations
21. Necrotizing vasculitis at granulocyte‐macrophage‐colony‐stimulating factor injection sites
22. Granulocyte‐macrophage colony‐stimulating factor and vasculitis
23. Leucocytoclastic vasculitis during GM‐CSF therapy
24. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony‐stimulating factor
25. Bullous pyoderma gangrenosum after granulocyte colony‐stimulating factor treatment
26. Failure of recombinant human granulocyte‐macrophage colony‐stimulating factor therapy in aplastic anemia patients with very severe neutropenia
27. Effect of recombinant human granulocyte‐macrophage colony‐stimulating factor on chemotherapy‐induced my‐elosuppression
28. M‐VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience
29. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M‐VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study
30. Acute vascular ischemic events after cisplatin‐based combination chemotherapy for germ‐cell tumors of the testis
31. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer
32. Arterial thrombosis after treatment with bleomycin and cisplatin
33. Phase I trial of escalating doses of cisplatin in hypertonic saline
34. The natural history of splenic infarction
35. Thromboembolic splenic infarction